MYO

Myomo, Inc.

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to suppor t the arm and restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. It is currently the only marketed device that, sensing a patient\'s own EMG signals through non-invasive sensors on the arm, can restore an individual\'s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. Many are able to return to work, live independently and reduce their cost of care. Myomo is headquartered in Cambridge, Massachusetts, with sales and clinical professionals across the U.S and representatives internationally.

Myomo, Inc. (MYO) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B-); its weakest is Growth (C+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
B-
Factor Score 3.0 / 5.0
Growth
C+
Factor Score 2.6 / 5.0
Profitability
C+
Factor Score 2.7 / 5.0
Momentum
B-
Factor Score 3.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -5.5
EV / EBITDA -5.9
Rev Growth YoY 21.3%
Gross Margin 68.4%
Price Return 3M -29.6%
Price Return 12M 42.4%
Catalyst Signal 0.00
Market Cap $48.5M
TTM Revenue $43.3M
Price / Sales 1.1
ROE -123.8%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (3.0) C+ (2.6) C+ (2.7) B- (3.0) C+ (2.6) C+ (2.8)
2026-11-06 B- (3.0) C+ (2.6) C+ (2.7) B+ (3.6) C+ (2.7) B- (2.9)
2026-10-30 B- (3.0) C+ (2.5) C+ (2.8) A (4.4) C+ (2.7) B- (3.1)
2026-10-23 B- (3.0) C+ (2.5) C+ (2.8) A (4.3) C+ (2.6) B- (3.1)
2026-10-16 B- (3.0) C+ (2.5) C+ (2.8) A- (4.0) C+ (2.6) B- (3.0)
Page 1 of 8
…